Storia in 6 fonti

Novartis investors turn spotlight on M&A after trial setbacks

By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) - Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

finance.yahoo.comStai leggendo1 g fa

Novartis investors turn spotlight on M&A after trial setbacks

Novartis shares fell 11% as del-desiran (from $12B Avidity deal) failed trials, erasing $30B and raising M&A concerns. Mega-acquisitions concentrating R&D risk face investor scrutiny; market signals shift toward smaller $5-10B bolt-on deals, impacting M&A budgets and R&D strategy.

originale

Timeline cronologica

mercoledì 9 settembre 2026·letemps.ch
Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps
Le géant pharmaceutique bâlois a reconnu mardi qu’un traitement en cours d’étude contre une maladie neuromusculaire n’avait pas atteint ses objectifs. Il s’agit du deuxième échec…
giovedì 10 settembre 2026·fiercepharma.com
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking. | Novartis’ recent dual clinical setbacks have…

Novartis investors turn spotlight on M&A after trial setbacks

Confronto fonti

Novartis investors turn spotlight on M&A after trial setbacks

Timeline cronologica

Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks - Novartis (N

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

Major Novartis shareholder calls for board shake-up after drug trial setbacks

Novartis stock in hot water after another key failure

Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps

Major Novartis shareholder calls for board shake-up after drug trial setbacks

Novartis stock in hot water after another key failure

Novartis investors turn spotlight on M&A after trial setbacks

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks - Novartis (N

Drug Trial Setbacks Raise Questions Over Novartis (NVS)’s Growth Pipeline